|
|
||||||||
CUTTING EDGE |

*
Departments of Immunology and
Molecular Biotechnology, University of Washington, Seattle, WA 98195
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Previous studies suggested that CD8+ T cells might participate as effector or regulatory cells in EAE (7, 8, 9, 10). The existence of MHC class I-restricted T cells specific for naturally processed MBP in vivo has not been demonstrated, although human CD8+ T cells specific for a peptide of MBP have been isolated in vitro (11). These issues motivated us to study the MHC class I-restricted immune response to MBP and examine the potential role of endogenous MBP in shaping the CTL repertoire specific for this Ag.
| Materials and Methods |
|---|
|
|
|---|
C3HeB/FeJ and C3HeB/FeJ-MBPshi/+ were purchased from The Jackson Laboratory (Bar Harbor, ME). MBPshi/+ and MBPshi/shi (MBP-/-) mice (12, 13, 14) were identified by PCR (15) and whole body tremor.
Construction of a recombinant adenovirus expressing MBP
An E1 inserted, Ad5 recombinant adenovirus expressing MBP (Ad/MBP) was generated by inserting the plasmid pXCJL.1 containing an MBP cDNA (16) into an E1-deficient Ad5 adenovirus pJM17 (17, 18). In addition, a L929 cell line expressing MBP (L/MBP) was generated using the expression vector pcDNA3.1 (Invitrogen, Carlsbad, CA) containing the MBP cDNA (16). Expression of MBP mRNA was detected in cells infected with Ad/MBP and L/MBP cells by RT-PCR (19). A recombinant vaccinia virus expressing MBP (Vac/MBP) (20), was obtained from Therion Biologics (Cambridge, MA).
Synthetic peptides
Peptides were synthesized using TBOC chemistry on a model 430A peptide synthesizer (Applied Biosystems, Foster City, CA). The peptides were purified by reverse-phase HPLC, and all peptides were analyzed for purity by mass spectrometry.
Infection of mice and generation of MBP-specific T cell lines and clones
Mice were infected with 107 pfu Ad/MBP virus i.p. or 106 pfu Vac/MBP i.v. After 3 wk infection, immunized mice were harvested and 3 x 107 splenocytes were stimulated in vitro in 10-ml cultures with 1 x 106 irradiated target cells in RPMI 1640 media supplemented with 10% FCS. All procedures have been approved by the animal care committee at the University of Washington.
51Cr release assays
Target cells were infected with virus at a multiplicity of infection of 10 and incubated for 72 h for adenovirus and 12 h for vaccinia virus in growth media before labeling with chromium. Target cells were then incubated with 100 µCi of (51Cr)O4 (Amersham, Arlington Heights, IL) for 60 min, washed, and incubated with effector cells in a standard 4-h 51Cr release assay. The percent lysis was calculated as (51Cr release in the presence of CTLs spontaneous 51Cr release) x 100/(total 51Cr release in 2% Nonidet P-40 spontaneous 51Cr release).
Mapping of MBP epitopes and MHC restriction allele
MBP-specific T cell lines and clones were tested in 51Cr release assays with L cells pulsed for 18 h with 30 µM overlapping 20- to 23-mer synthetic peptides in RPMI to allow processing of suboptimal peptides before chromium labeling. The 9-mer peptides were preloaded to L cells, RMA-S cells, and RMA-S-Kk (kindly provided by Dr. Peter Cresswell, Yale University, New Haven, CT) at known dilutions for 30 min before the addition of effector cells.
| Results and Discussion |
|---|
|
|
|---|
C3H MBP-/- and MBP+/+ mice were infected i.p. with Ad/MBP. Splenocytes from infected mice were harvested and stimulated in vitro for 5 days with L/MBP. The stimulated splenocytes were then tested for their ability to lyse syngeneic target cells expressing MBP. From 14 of 16 MBP-/-mice, MBP-specific killing was observed. In contrast, no MBP-specific killing by T cells from wild-type mice was observed (0 of 15 mice; data not shown).
Because adenovirus has a restricted tropism, a second protocol was used
to assess MBP-specific cytotoxic T cell responses. Splenocytes from
mice infected with Vac/MBP were stimulated in vitro with irradiated L
cells infected with Vac/MBP. From all MBP+/+ and
MBP-/- mice, a potent vaccinia-specific T cell
response was generated. In contrast, an MBP-specific cytotoxic T cell
response was generated only in MBP-/- mice (13
of 13) but not in MBP+/+ mice (0 of 15) (Fig. 1
, A and B).
|
Twenty-one MBP-specific T cell clones were established from three
MBP-/- mice after one in vitro stimulation by
limiting dilution cloning. All clones were of the 
TCR+, CD8+ lineage (data
not shown). The fine specificity of three MBP-specific T cell clones
was determined using target cells pulsed with a panel of overlapping
peptides comprising the entire MBP protein. All three clones
specifically lysed target cells pulsed with
MBP6891 but no other peptides (Fig. 2
A). The remaining 18 T cell
clones were tested and specifically lysed target cells presenting this
peptide (data not shown).
|
To identify the core 9-mer epitope that is targeted by MBP-specific
CTLs, we first evaluated the sequence within
MBP6891 for an H-2k class
I binding motif (21). The overlapping 9-mer peptides
MBP7886, MBP7987, and
MBP8088 were tested. All MBP-specific CTL
clones recognized target cells coated with the
MBP7987 peptide epitope in a dose-dependant
manner (Fig. 3
, and data not shown).
These results indicate that MBP7987 represents
the naturally processed MBP-specific CTL epitope in C3H mice.
|
To identify the MHC allele that presents
MBP7987 to CD8+ cytotoxic
T cells, Con A blasts from the B10 MHC congenic strains B10.A(4R),
B10.MBR, and C3H were used as target cells. The results suggested that
the MBP7987 peptide is presented by the MHC
class I allele Kk (data not shown). To confirm
this result, we tested the ability of RMA-S cells and RMA-S cells
transfected with Kk to present the MBP epitope.
RMA-S-Kk cells were able to present the MBP
epitope, while untransfected RMA-S cells were not (Fig. 4
).
|
The results described above demonstrate that MBP-specific, MHC
class I-restricted cytotoxic T cells are present in the periphery of
MBP-deficient mice and that these T cells undergo tolerance in
wild-type mice that express endogenous MBP. These observations raised
the question of where tolerance to MHC class I epitopes of MBP occurs
in vivo. To address this issue, we used two independent protocols to
assess whether peripheral mechanisms are responsible for tolerance of
MBP-specific CTLs. Results are shown in Table I
. In the first experiment, MBP-specific
T cells (group 1) and vaccinia-specific T cells (group 2) were
transferred into SCID mice to test for retention of Ag-specific
responses. 51Cr release assays were performed
with the T cell lines just before transfer to confirm their CTL
activity and the recipient SCID mice were bled 1 wk after transfer to
assure survival of T cells after transfer (data not shown). After 4 wk,
spleens from recipient mice were harvested and tested in CTL assays.
Vaccinia-specific T cells were easily detected in recipients of
vaccinia-specific T cells. In contrast, MBP-specific CTL activity was
not detected in any recipients of MBP-specific CTLs. In a separate
approach, we asked whether naive peripheral T cells from
MBP-/- mice that have not been exposed to MBP
would undergo tolerance when transferred into the periphery of
MBP+/+ mice. SCID mice were reconstituted with
naive lymphocytes isolated from MBP-/- (group
3) and MBP+/+ (group 4) mice. The mice were bled
1 wk after transfer to assure that the lymphocytes had reconstituted
all mice equally. Four weeks after reconstitution, mice were infected
with either Ad/MBP or Vac/MBP. Potent vaccinia-specific responses were
generated in mice that received either MBP-/-
or MBP+/+ lymphocytes when Vac/MBP was used both
as the immunogen and to restimulate the T cells in vitro. We attempted
to generate MBP-specific CTL responses by immunizing the mice with
either Ad/MBP or Vac/MBP. However, no responses were detected in SCID
mice reconstituted with lymphocytes from either
MBP-/- or MBP+/+. Control
MBP-/- mice (group 5) but not
MBP+/+ mice (group 6) infected and restimulated
using these protocols at the same time as the recipient mice generated
MBP-specific CTL responses. Therefore, although these data do not
exclude a role for central tolerance mechanisms, they indicate that
peripheral mechanisms eliminate functional MBP-specific CTL responses
from mice expressing endogenous MBP.
|
Recently, it has been demonstrated that some MHC class II-restricted T cells specific for MBP are also efficiently tolerized in wild-type mice (15, 25). The tolerogenic CD4+ T cell epitopes of MBP in H-2u mice have not been found in any of the golli-MBP protein. Therefore, immune tolerance in MHC class II-restricted T cells can be mediated by endogenous expression of classical MBP. Because of differences in tissue distribution and MHC class, it is possible that MHC class I- and class II-restricted T cells specific for MBP undergo tolerance via different mechanisms.
The studies reported here describe a model system in which MHC class I-restricted T cells specific for MBP can be generated and analyzed for their contribution to autoimmune disease. The identification of naturally occurring MHC class I-restricted epitopes allows monitoring of MBP-specific CTL responses during the course of disease. Therefore, the ability of MBP-specific CTLs to be activated by (or contribute to) determinant spreading can be investigated (26, 27, 28). This model system provides a novel approach to define the role of CNS Ag-specific CD8+ CTLs in the pathogenesis of autoimmune disease.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Joan Goverman, Department of Molecular Biotechnology, Box 357650, University of Washington, Seattle, WA 98195. E-mail address: ![]()
3 Abbreviations used in this paper: EAE, experimental autoimmune encephalomyelitis; MS, multiple sclerosis; MBP, myelin basic protein; Ad/MBP, adenovirus expressing MBP; L/MBP, L929 cell line expressing MBP; Vac/MBP, vaccinia virus expressing MBP. ![]()
Received for publication April 6, 1999. Accepted for publication June 1, 1999.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
Q. JI and J. GOVERMAN Experimental Autoimmune Encephalomyelitis Mediated by CD8+ T Cells Ann. N.Y. Acad. Sci., April 1, 2007; 1103(1): 157 - 166. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Tsunoda, L.-Q. Kuang, M. Kobayashi-Warren, and R. S. Fujinami Central Nervous System Pathology Caused by Autoreactive CD8+ T-Cell Clones following Virus Infection J. Virol., December 1, 2005; 79(23): 14640 - 14646. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Friese and L. Fugger Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? Brain, August 1, 2005; 128(8): 1747 - 1763. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. S. Huseby, D. Liggitt, T. Brabb, B. Schnabel, C. Ohlen, and J. Goverman A Pathogenic Role for Myelin-specific CD8+ T Cells in a Model for Multiple Sclerosis J. Exp. Med., September 4, 2001; 194(5): 669 - 676. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. S. Huseby and J. Goverman Tolerating the Nervous System: A Delicate Balance J. Exp. Med., February 28, 2000; 191(5): 757 - 760. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |